RE: RNS18 Sep 2023 07:35
I like this bit..
Eroxon® sales are on track to exceed expectations versus its original first year forecasts, with Eroxon® expected to gain around a 20% share of the clinically proven ED treatment market, with these being largely incremental, demonstrating encouraging signs of consumer acceptance and repeat purchase. Feedback has been positive, with a very low level of complaints received regarding lack of efficacy and side effects, which the Futura Board believes illustrates a high degree of consumer satisfaction.
Over the next six months or so, our distributors will look to move into the next phase of its rollout and launch of Eroxon® with at least a further ten new country launches.